NetworkNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Featured in Research Report
Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve survival and/or quality of life for patients with high unmet medical need conditions, was featured in an institutional research report by Craig-Hallum Capital Group LLC. The report discusses Craig-Hallum’s research coverage of PCSA and details the company’s experienced management team and its ownership rights to five programs that are de-risked by existing data. The piece reads, “By early next year, PCSA expects to begin three clinical trials – PCS499 in Phase IIb to treat necrobiosis lipoidica (‘NL’), PCS6422 in Phase 1b as an adjunct to the chemotherapy 5-FU,…







